GLP-1 vs. CPAP Market Outlook
Industry Insights
MARKET AT A GLANCE
For many years, CPAP therapy has been the standard treatment for people with moderate to severe obstructive sleep apnea (OSA). CPAP works by physically preventing the airway from collapsing during sleep, which reduces breathing pauses, snoring, and daytime fatigue almost right away.
Recently, a new class of medications known as GLP1 drugs (best known for weight loss and diabetes treatment) has entered the conversation. With the FDA approval of tirzepatide for sleep apnea in people
HOW CPAP AND GLP-1S ACTUALLY WORK
CPAP treats sleep apnea at its source: the airway. By gently blowing air into the throat, CPAP prevents the airway from collapsing during sleep. Because of this mechanical effect, CPAP works quickly and consistently, regardless of a person’s weight, metabolism, or overall health.
GLP-1 medications work more indirectly. They help people lose significant amounts of weight, which can reduce pressure on the airway over time. For patients whose sleep apnea is closely tied to excess weight,
OSA PREVALENCE
with obesity, many are asking: Will medications replace CPAP?
When you step back and look across several datapoints, the answer is clearer and more balanced than some might think. Research shows that GLP1 medications and CPAP treat sleep apnea in very different ways, and for most patients, they work best together rather than in competition.
this can lessen the severity of the condition—but it happens gradually, and results vary widely from person to person.
This difference explains why CPAP almost always delivers larger and faster improvements in breathing during sleep, while GLP-1s shine in improving weight, blood sugar, and broader metabolic health.
DIABETES PREVALENCE
WHAT HEAD-TO-HEAD STUDIES SHOW
In studies that directly compare CPAP to GLP-1–based weight loss, CPAP consistently leads to bigger improvements in sleep apnea symptoms. In one welldesigned clinical trial, patients using CPAP saw much greater reductions in breathing interruptions than those relying on weight loss medication alone—even when the medication led to meaningful weight loss.
CPAP also improved early signs of cardiovascular stress, something that weight loss alone did not fully achieve. This suggests that keeping the airway open at night has unique health benefits beyond weight reduction.
When CPAP and GLP-1 therapy were used together, outcomes were strongest, reinforcing the idea that these treatments complement each other.
When researchers pooled data from dozens of studies involving thousands of patients, the results were consistent:
• CPAP ranked highest for improving breathing during sleep and reducing daytime sleepiness
• GLP-1 medications ranked highest for weight
loss and metabolic health
• Using both together produced the most balanced and durable benefits
Taken together, this evidence points to a clear division of labor: CPAP controls the airway; GLP-1s improve the underlying metabolic drivers of disease in certain patients.
Large, real-world studies tracking hundreds of thousands—and now more than one million— patients tell a reassuring story: people taking GLP-1 medications are not abandoning CPAP therapy. CPAP usage rates are similar among GLP-1 users and nonusers. Patients who remain consistent with their GLP-1 medication often use CPAP more consistently, and those prescribed both treatments are more likely to initiate CPAP and stick with it long term. Rather than disrupting sleep apnea care, GLP-1 medications appear to be bringing more patients into formal diagnosis and sustained treatment pathways.
CONCLUSION
The practical takeaway from the research is clear: CPAP remains the most reliable and immediate treatment for moderate to severe sleep apnea, while GLP-1 medications can meaningfully reduce disease severity for patients whose apnea is driven by obesity, with the best outcomes occurring when both therapies are used together in the right patients. GLP-1s will undoubtedly change the sleep apnea landscape—some patients may reduce their reliance on CPAP, and more individuals may be diagnosed and treated earlier—but sleep apnea driven by airway anatomy, aging, or non-weight-related factors will continue to require CPAP as the foundation of care.
[1]: Continuous Positive Airway Pressure But Not GLP-1–Mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea
[2]: Diabetes, Obesity & Metabolism
[3]: Comparative Effectiveness of GLP-1 Receptor Agonists in Obstructive Sleep Apnea Management: A Bayesian Network Meta Analysis With Intervention Ranking
[4]: Effect of Liraglutide 3.0 mg in Individuals With Obesity and Moderate or Severe Obstructive Sleep Apnea: The SCALE Sleep Apnea Randomized Clinical Trial
[5]: Glucagon Like Peptide 1 Receptor Agonists for Obstructive Sleep Apnea: A Systematic Review and Meta Analysis
[6]: Efficacy and Safety of GLP-1 Receptor Agonists for Treatment of Obstructive Sleep Apnea
[7]: Glucagon Like Peptide 1 Receptor Agonist and Positive Airway Pressure Use in Patients With OSA and Obesity
[8]: Real World GLP-1 Adherence in Patients With Treated Obstructive Sleep Apnea
[9]: New ResMed Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of PAP Therapy
VGM Industry Insights provides data-driven analysis and trends within the durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) sector. Our focus areas include market trends, innovation, and strategic decision-making, helping stakeholders stay informed and competitive. We are committed to a forward-thinking approach, continuously monitoring industry developments to drive progress and innovation.
ALAN MORRIS SVP of Strategy and Business Development
TYLER COULANDER Market Strategy Manager
